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Abstract 
Objective: Because a centre effect can sometimes exist in HIV treatment, we sought to 
measure the heterogeneity of French hospital departments delivering HIV care and to 
test the presence of such an effect on adherence and response to HAART. 
Methods: The ANRS-EN12-VESPA study is a nationally representative two-stage 
cross-sectional survey conducted in France in 2003 and covering 102 hospital 
departments providing HIV care. Each department described its HIV care activities and 
care provision. Analyses of adherence and four indicators of treatment outcome were 
restricted to the 699 patients diagnosed from 1996 onwards and treated with HAART 
for at least 6 months. The variability between departments was assessed with random-
effect models for binary outcomes. 
Results: The departments delivering HIV care proved to be somewhat heterogeneous in 
numerous respects, including their size and their onsite provision of consultancies and 
other services, as well as the characteristics of their patient population. Mean observed 
adherence was 63.3%, and the means of the different treatment failure indicators ranged 
from 6.1% to 59.8%. The departments showed some variability for these outcomes, but 
no significant centre effect was detected. 
Conclusions: Despite the heterogeneity of the specific types of medical services offered 
by the hospitals providing HIV care, the nationwide treatment results appear 
homogeneous. This homogeneity could be attributed to the widespread and consistent 
application of therapeutic guidelines, which are regularly updated by consensus. 
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Introduction 
Since the advent of AIDS, equality and non-discrimination in access to prevention and 
treatment have been major issues, because so high a percentage of patients belongs to 
stigmatised or disadvantaged groups, such as drug users, ethnic minorities, immigrants 
or women. Disadvantaged groups have been shown to have less access to zidovudine 
treatment [1] and pneumocystis carinii pneumonia (PCP) prophylaxis [2]; they also start 
HAART later [3]. Aside from the barriers to health care due to patients’ financial 
situation and educational level, physicians’ anticipation that patient compliance will be 
poor [4,5] has been shown to explain delayed initiation of HAART. Moreover, several 
US studies, conducted mainly before the advent of HAART, identified physician 
experience as a determinant of progression to AIDS and survival [6,7,8,9,10]. 
 
Since a very high level of adherence is required to fully benefit from HAART, a 
multidisciplinary approach to HIV care is need to support patients and help them deal 
with the practical, social and emotional dimensions of living with HIV [11, 12]. 
Hospitals and health care centres should provide comprehensive HIV care with a range 
of medical and social services to achieve the best possible outcomes.  Rapid progress in 
clinical research necessitates the regular updating of treatment recommendations. 
Physicians should update their practice regarding treatment so that all patients can 
benefit from the most recent scientific advances. Such rapid changes might vary 
according to physician characteristics, type of setting and size of HIV caseload. 
 
The purpose of this paper is to describe the heterogeneity of the hospital HIV treatment 
provided in France and its effect on treatment outcome.  
Material and methods  
Study design 
This analysis used data from the 2003 ANRS-EN12-VESPA study, a large nationally 
representative two-stage cross-sectional survey, aimed at studying the social situation of 
HIV-infected persons in France. The study design has been detailed elsewhere [13]. 85 
hospitals providing HIV care were randomly selected among the 143 French hospitals 
with a HIV caseload greater than 60 patients, stratifying on geographic location and size 
of HIV caseload. As some large hospitals had several departments serving patients with 
HIV, the 85 hospitals were composed of 102 departments providing HIV care. Doctors 
in each of these departments randomly recruited a sample of outpatients (representing 
about 5% of their caseload) among those with the following eligibility criteria: having 
been diagnosed with HIV-1 infection for at least 6 months, aged 18 or older, and, if not 
a French citizen, having lived in France for at least 6 months. Patients who understood 
French very poorly were excluded. The study design and informed consent procedures 
complied with the ethical and statutory requirements of the French Data Protection 
Authority (Commission Nationale Informatique et Libertés).  
 
 
Information collected 
Information was collected for each hospital department and for each individual patient.  
In each department, a clinical research assistant completed an information sheet  on the 
current HIV patient caseload, department capacity (number of physicians, of inpatient 
beds, of day hospital beds, and of weekly outpatient appointments), participation in 
research activities (cohort studies and clinical trials), onsite provision of a range of 
specialised consultations and care (nutrition, hepatolology, dermatology, drug treatment 
liaison team, psychiatry etc.), promotion of treatment adherence (group or individual 
education, leaflets, pillbox provision etc.), and the onsite presence of PLWHA groups. 
 
Information was collected on the following characteristics for all eligible patients: sex, 
age, employment status, mode of transmission and last known CD4 cell count and viral 
load. This data allowed for the assessment of participation bias. 
 
Participating patients answered a questionnaire administered in a face-to-face interview. 
Detailed information was collected on socio-demographic characteristics and on a wide 
range of social conditions (health care access and use, health behaviour, occupational 
status, income, housing, social support, HIV disclosure, discriminations encountered, 
sexual activity and reproductive life). Physicians recorded for each patient the mode of 
HIV acquisition, disease characteristics, and treatment information (date of diagnosis, 
date of HAART initiation, clinical stage, CD4 count and viral load at diagnosis, at 
HAART initiation and last known values).  
 
Variables of interest 
The heterogeneity of the departments delivering HIV care was studied for adherence 
and various measures of treatment outcome. 
Adherence to HAART was assessed with a dichotomous outcome (high versus 
moderate or poor adherence) validated in previous cohort studies [14,15]. First, 
participants were asked about their compliance with HAART in the prior 7 days. They 
had to choose among the following items, each corresponding to a level of adherence: ‘I 
have followed scrupulously my treatment’ (=high adherence), ‘I have followed my 
treatment despite some small lapses’ (=moderate adherence), ‘I have frequently 
modified doses or time schedule’, ‘I have almost never complied with prescription 
instructions’, ‘I have stopped treatment’ (=poor adherence). Then, participants were 
asked whether or not they had missed at least one dose during the previous week-end, 
whether they had taken the whole daily dose in only one take in the previous 7 days, or 
whether they had failed to respect the time schedule for at least one dose during the 
same period. Participants previously ranked as highly adherents but who had answered 
‘yes’ to one of these three questions were reallocated to the ‘moderate adherence’ 
category. 
 
Treatment outcome was assessed using four different indicators, three defining failure 
and one denoting success: 
• Immunological response was defined as the absence of an increase of ≥100 CD4 
cells/mm3 between HAART initiation and data collection. This threshold was 
chosen on the basis of the review by May and colleagues [16], showing a 
median 100 cells increase in CD4 cell count in the first 6 month on HAART, 
which was here the minimum duration.  
• Virological failure was defined as having detectable HIV-RNA (<400 copies/ml) 
at data collection; 
• Immunovirological failure was defined as the combination of a CD4 cell 
count ≤200/mm3 and detectable HIV-RNA at data collection;  
• Lastly, immunovirological success was defined as the combination of a CD4 cell 
count ≥ 500/mm3 and undetectable HIV-RNA at data collection. [17] 
 Population of interest 
The VESPA study included 2932 participants from 102 different departments. For the 
present analysis, we included only the 699 participants (of 97 different departments) 
who had been diagnosed in 1996 or later and had received HAART for at least 6 months 
at the time of the study. The medical history of patients diagnosed before and after the 
HAART era is indeed too different to be pooled in an analysis on this topic. 
Furthermore, the much higher mortality before 1996 indicates much greater selection 
bias among the patients diagnosed before that year. A minimum of 6 months is assumed 
necessary before the treatment can be judged effective and thus classified as a success 
or failure. 
 
Statistical methods 
For each of the five outcomes, the existence of a centre effect was assessed by testing 
the department as a random variable in a binary mixed model, without any other 
covariate. If this random variable appeared to be significant, the next step of the analysis 
was to include in the models covariates measured at the individual level (age, sex, 
sexual orientation, immigration status, education, HCV coinfection, time since HAART 
initiation, CD4 cell count at HAART initiation, addictive behaviour, current trial 
participation, side effects, and adherence, when relevant). If the random variable was no 
longer significant, then the previously found effect was due only to differences in 
population structure and a given patient had the same chance of treatment outcome 
regardless of facility.  
Because including centres with very few subjects could result in a lack of robustness, 
we performed a sensitivity analysis by restricting the analysis to departments with at 
least five participating patients and then with at least 10 participants. All statistical 
analyses were performed using SAS 9.1. 
 
Results 
Characteristics of departments regarding service provision 
Among the 102 departments, the median size of the HIV caseload at data collection was 
400 (IQR: [230-750]). The median number of physicians providing HIV care per 
department was 3 (IQR: [2-6]), and the median number of outpatient appointments per 
week was 7 (IQR: [5-10]). Half of these departments specialised in infectious diseases, 
a quarter in internal medicine, and the others in haematology, dermatology, 
pneumonology or hepatology. Internal medicine departments tended to provide a wider 
range of consultant services than the others. These most often included nutrition (85%), 
followed by dermatology (55%) and psychiatry (53%). More rarely offered were 
hepatology (36%), addiction liaison service (39%), endocrinology (32%), neurology 
(29%) and gynaecology (28%). Individual sessions on adherence education were 
provided in 83% of the departments, and PLWHA organisations offered an onsite 
presence in 41%. Most departments participated in clinical research, such as clinical 
trials (83%) or cohort studies (79%).  
 
Characteristics of participants 
The median age of these patients was 42 years (IQR: [35-51]); men accounted for 75% 
of the sample; 39% self-identified as homo- or bisexual men, 6% were IDU (4% men, 
2% women), 29% were French-born heterosexuals with no IDU history (19% men, 10% 
women) and 26% were immigrant heterosexuals with no IDU history (13% men and 
women). Most of the heterosexual immigrants came from sub-Saharan Africa (72% of 
the men and 86% of the women). Late diagnosis (defined either as symptoms of clinical 
AIDS or CD4 cell count <200/mm3 during the year following diagnosis) was observed 
in 43% of this population diagnosed in or after 1996. At HAART initiation, 49% had a 
CD4 cell count < 200 cells/ml. 
 
Structure of departments’ population 
As shown in Table 1, these different categories of participants were not uniformly 
distributed among the hospital departments: the structure of the patient population 
appeared quite heterogeneous across centres. The median proportion of immigrants was 
20%, with an IQR from 0% to 40%. While men constituted a majority of patients, with 
a median proportion of 75%, this rate varied substantially (IQR: [60%-90%]). The 
median proportion of patients under 40 was 43% (IQR: [20%-50%]), and the median 
proportion of patients with late diagnosis was 40% (IQR: [29%-57%]). Few 
departments treated patients with an IDU history: the median proportion of these 
patients was 0 and the upper quartile 12.5%. 
For the analysis population, the mean number of participants per department was 7.2 
and the median 6 (IQR: [1 – 10]). 
 
Adherence and treatment outcomes 
Table 2 shows the distribution of adherence and treatment outcomes measured for each 
hospital department and the related tests for centre effects. The mean percentage of 
highly adherent participants was 63.3%. The heterogeneity between departments was 
rather large: the IQR varied from 50% to 80%, with a median adherence rate of 62%. 
However, the existence of a centre effect was rejected when we tested the department as 
a random variable (p = 0.275). 
 
The overall rate of immunological failure was 22.6%, with a departments’ median of 
20% and an IQR of 0% to 40%. No centre effect existed here either (p = 0.215). 
The overall rate of virological failure was 12.5%, with a median rate of 7.7%. Only a 
quarter of the departments had rates above 20%, and 44.3% had no virological failures. 
Again, no centre effect was detected (p =0.098). 
 
The mean immunovirological failure was 6.1%. Three quarters of the departments had a 
failure rate under 12.5%, and 61% had no participants in immunovirological failure. 
The existence of a centre effect was rejected with a p-value of 0.181. 
 
The criteria defining immunovirological treatment success, i.e. a CD4 count over 
500/ml and undetectable HIV-RNA, were met by 40.2% of patients. The median 
department success rate was 36.3%: a quarter had rates only below 13.3%, and another 
quarter had rates above 50%. The random variable appeared to be significant (p=0.026) 
for this indicator. A centre effect thus existed, at least when tested for the entire 
population analysed. Nevertheless, the random term was not significant when a 
covariate measured on the individual level was introduced, such as the patient CD4 cell 
count≤200/mm3 at HAART initiation (p=0.094) or the patients’ immigration status 
(p=0.200). 
Our sensitivity analysis consisted in rerunning these models with restricting the analysis 
population first to the 601 patients of the 60 departments that had at least five 
participating patients, and secondly to the 378 patients of the 26 departments that had at 
least ten participating patients. 
For adherence, as for the three first indicators of treatment failure, the absence of a 
centre effect was confirmed. Concerning immunovirological success, the random 
variable was still significant in the first restriction (p=0.030) and almost still significant 
in the second restriction to departments with at least 10 patients (p=0.053). Adjusting on 
covariates measured on the individual level returned as previously a non-significant 
random term. 
 
Discussion 
This study used data from a large random sample of hospitals providing HIV care, both 
representative at the national level and very diverse in terms of size, region, localisation 
in either metropolitan areas or medium-sized cities, activity, and specialisation. We 
observed a significant variation in the size of the HIV caseload, the provision of 
consultant services offered onsite, patient education to increase adherence, and support 
from PLWHA organisations. Nonetheless no centre effect was identified, either for 
adherence to treatment or in HAART outcomes: in France, regardless of where HIV 
patients are treated for their infection, treatment success or failure depends upon 
individual determinants. In a previous study of this population, we found that aside from 
the well-established determinants (such as age, time on HAART, history of interruption 
in HIV care, suboptimal adherence, HCV co-infection, CD4 cell count and HIV-RNA 
level and AIDS at HAART initiation), immigrant status and continuing IV drug use 
were associated with a greater risk of treatment failure [13]. 
 
Because of the cross-sectional design of the VESPA study, treatment failure might have 
been underestimated: deaths that occurred between diagnosis and data collection were 
not taken into account in the calculation of failure rate. In the HAART era, mortality 
remains much higher among patients diagnosed with advanced infection than among 
patients diagnosed before reaching the criteria for treatment initiation [18]. In the 
former group, the physician’s experience may play a critical role [4,6,8,9,10].  
 
Our study considered only hospitals caring for a substantial number (60 or more) of 
persons with HIV. Patients followed in smaller HIV-oriented services are not included 
although they might have different HIV outcomes. However, the hospitals included 
provided care for an estimated 90% of the HIV patient population followed in hospitals. 
 
Random sampling ensured the representativeness of each hospital department caseload, 
but differential participation was related to individual patient characteristics, including 
lower CD4 cell counts. Participation bias might thus explain the absence of centre 
effects, especially if patients with poor treatment outcomes had tended to participate 
less in the hospitals with the poorest outcome rates. As last known CD4 cell count and 
viral load were available for every eligible patient, we were able to verify that this was 
not the case, using a mixed binary model which explained the participation of eligible 
patients by their health status and the treatment outcome rate of their hospital 
department. 
 Despite a low number of participants in some departments, we believe that the absence 
of an observed centre effect is unlikely to be due to lack of power. The assumptions of 
the random coefficient model we use seem appropriate here, and neither the estimates 
nor p values changed substantially when the analysis was restricted to the two 
subsamples with the hospital departments reaching either five or 10 patients with at 
least 6 months on HAART. 
 
The data were collected in 2003, and could perhaps not reflect the current situation. The 
treatment practices and the structure of the patient population have evolved. However, 
since the context of high innovation and frequent improvements in treatment practices is 
the same today as it was from 1996 to 2003, it is plausible that the observed 
homogeneity still applies today. 
 
With these limitations, adherence and response to HAART appeared not different across 
treatment sites despite the diversity in medical care provision. These findings contrast 
with studies in the US during the 1980s and early 1990s [1,2,3,4]. The very high 
effectiveness of the current combinations of antiretroviral drugs, when accessible to all 
who need them, may well be acknowledged as the principal factor for the observed 
results. The frequent updating of treatment guidelines (at least every two year) may also 
contribute to the improvement of treatment practices. Moreover, in France, HIV care 
has been coordinated at the local level since 1988, to facilitate scientific 
communication, availability of the range of treatment services and care coordination. 
Dissemination of recent scientific findings among HIV specialists may be facilitated by 
their participation in clinical research: 83% of the departments included participate in 
clinical trials and 79% in cohort studies. Such participation provides the opportunity of 
frequent contacts between HIV experts at national and international levels.  
 
Two decades after the advent of AIDS, at country level, HIV care has become a lay 
medical specialty. The HIV medical community has remained relatively small, while 
becoming closely networked. The pioneers have not yet started to retire [19]. These 
factors, combined with the experience acquired, may account for the relatively 
homogeneity of good care that could explain the results we observed in the VESPA 
study. International goals for 2010 include universal antiretroviral treatment for all who 
need it [20], including in countries with a scarcity of skilled human resources. Studies 
show that when treatment is provided at no charge, its efficacy reach the same levels in 
southern countries as it does in northern countries [21]. Accessibility will require that 
antiretroviral treatment be provided through medical facilities in the community. Long-
term networking and training of HIV care providers to improve and maintain high 
standard skills should be planned to ensure the equal outcomes that should accompany 
truly equal access to effective treatment.  
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Table 1: Description of departments’ care provision, activities and HIV patient 
population (n=102) 
 
Department characteristics  
 Percent 
Onsite provision of consultant services  
Hepatology  36.3 
Endocrinology / metabolism  32.4 
Dietetic/Nutrition  85.3 
Gynaecology  27.5 
Dermatology  54.9 
Ophthalmology  24.5 
Neurology  29.4 
Psychiatry  52.9 
Pain  28.4 
Alcohol addiction 21.6 
Addiction liaison service 39.2 
Mobile palliative care team 56.9 
Pain treatment  66.7 
  
HIV Activities  
Participation in clinical research activities 83,3 
Participation in cohorts 79,4 
  
Other activities  
Individual education on adherence  42.2 
Onsite presence of PLWHA organisations 41.2 
Onsite presence of other organisations 20.6 
  
 Median [IQR] 
Size of current HIV caseload 400 [230-750] 
Number of physicians 3 [2-6] 
  
  
HIV patient population  
Proportion of migrants 20% [ 0%-40%] 
Proportion of men 75% [60%-90%] 
Proportion of patients under 40 years 43% [20%-50%] 
Proportion of patients with late diagnosis 40% [29%-57%] 
Proportion of patients with IDU history     0% [ 0%-12.5%]
  
 
 
Table 2: Distribution of adherence and treatment outcomes among the departments and tests of centre effects 
 
  All departments 
Nd= 97 
Np=699 
Departments with at least 5 patients
Nd=60 
Np=601 
 
 Departments with at least 10 patients
Nd=26 
Np=378 
  Mean Median IQR p-value*  Median IQR p-value*  Median IQR p-value* 
            
Adherence 63.3% 61.5% 50%-80% 0.275 60.0% 51%-79% 0.225  58.6% 50%-69% 0.885 
            
Immunological 20% 0%-40% 20.0% 14%-32%  19.4% 15%-30% 
failure1 
22.6%
  
0.215 
  
0.285 
   
0.312 
            
Virological 7.7% 0%-20% 14.3% 0%-20%  10.6% 5%-19% 
failure2 
12.5%
  
0.098 
  
0.176 
   
0.081 
            
Immuno-virological 0% 0%-12.5% 6.3% 0%-14%  7.7% 0%-13% 
failure3 
6.1% 
  
0.181 
  
0.177 
   
0.136 
            
Immuno-virological 36.4% 13.3%-50% 36.6% 29%-47%  36.6% 30%-47% 
success4 
40.2%
  
0.026 
  
0.030 
   
0.053 
Adjusted for CD4 cell count at HAART initiation: 0.094   0.092    0.170 
Adjusted for immigration status: 0.200    0.192    0.280 
 
Nd: Number of hospital departments 
Np: Number of patients 
* Hospital department entered as a random variable 
 
1 Less than 100 CD4 increase since HAART initiation 
2 HIV-RNA > 400 copies 
3 CD4 < 200 and HIV-RNA > 400 copies 
4 CD4≥500 and HIV-RNA<400 copies 
 
Mis en forme : Gauche : 
56,7 pt, Droite :  56,7 pt,
Haut :  56,7 pt, Bas :  56,7 pt,
Largeur :  841,9 pt, Hauteur : 
595,3 pt
Mis en forme : Justifié,
Retrait : Avant : 0 pt,
Interligne : simple,
Espacement automatique entre
les caractères asiatiques et
latins, Espacement
automatique entre les
caractères asiatiques et les
chiffres
